U.S. Food and Drug Administration, USA.
Eur J Pharm Sci. 2010 May 12;40(2):148-53. doi: 10.1016/j.ejps.2010.03.017. Epub 2010 Mar 27.
Modified-release products are complex dosage forms designed to release drug in a controlled manner to achieve desired efficacy and safety. Inappropriate control of drug release from such products may result in reduced efficacy or increased toxicity. This workshop provided an opportunity for pharmaceutical scientists from academia, industry and regulatory agencies to discuss current regulatory expectations and industry practices for demonstrating pharmaceutical equivalence and bioequivalence of MR products, further facilitating the establishment of regulatory standards for ensuring therapeutic equivalence of these products.
控释产品是复杂的剂型设计,旨在以可控的方式释放药物,以达到预期的疗效和安全性。如果不能适当控制此类产品的药物释放,可能会导致疗效降低或毒性增加。本次研讨会为来自学术界、工业界和监管机构的药物科学家提供了一个机会,讨论当前监管期望和行业实践,以证明控释产品的药物等效性和生物等效性,进一步促进建立监管标准,确保这些产品的治疗等效性。